Russian Federation
Russian Federation
Russian Federation
Russian Federation
Metformin — preparat pervoy linii lecheniya saharnogo diabeta (SD) 2 tipa. Prepyatstviem dlya ispol'zovaniya metformina v klinicheskoy praktike neredko sluzhat nezhelatel'nye reakcii, soprovozhdayuschie priem preparata. Cel'yu issledovaniya yavilos' issledovanie chastoty i haraktera nezhelatel'nyh reakciy na priem metformina u bol'nyh SD 2 tipa. V otkrytom nekontroliruemom, nerandomizirovannom, odnomomentnom issledovanii osuschestvleno nablyudenie za 125 bol'nymi SD 2 tipa, kotorym vpervye byl naznachen metformin. V pervye dni lecheniya nezhelatel'nye reakcii na priem preparata voznikli u treti pacientov (34,4±4,25%, 43/125). V bol'shinstve sluchaev oni byli obuslovleny rasstroystvami so storony zheludochno-kishechnogo trakta (97,7±2,3%, 42/43), sredi kotoryh dominirovala diareya (n=27, 64,3±7,4%). Eti rasstroystva u bol'shey chasti bol'nyh polnost'yu regressirovali v techenie 1–2 nedel' i nosili ustoychivyy harakter, yavivshiysya prichinoy otmeny preparata, tol'ko u 8 iz 125 (6,4±2,19%) pacientov. Ustanovlena svyaz' nezhelatel'nyh reakciy s gendernym faktorom. V pervye dni lecheniya zhaloby na plohuyu perenosimost' metformina chasche (primerno v 3 raza) pred'yavlyali zhenschiny (41,1±5,1%, 39/95), chem muzhchiny (13,5±6,21%, 4/30) (χ2=7,76, r=0,005). Priroda etoy zakonomernosti ne yasna. Vazhno, chto po mere uvelicheniya dlitel'nosti priema metformina gendernye razlichiya reakcii na preparat nivelirovalis'. Delaetsya vyvod o neobhodimosti prodolzheniy issledovaniy problemy nezhelatel'nyh reakciy, svyazannyh s priemom metformina.
metformin, saharnyy diabet 2 tipa, nezhelatel'nye reakcii na lekarstvo, rasstroystva zheludochno-kishechnogo trakta.
1. Mkrtumyan A.M. Metformin - obschepriznannyy preparat pervogo vybora u bol'nyh saharnym diabetom 2-go tipa // Medicinskiy sovet. - 2018. - № 4. - S. 20-27. DOI:https://doi.org/10.21518/2079-701X-2018-4-20-27
2. Demidova T.Yu., Drozdova I.N. Metformin: obzor sovremennyh dokazatel'nyh dannyh i mezhdunarodnyh rekomendaciy // Terapiya. - 2017. - № 2(12). - S. 95-100.
3. Madyanov I.V., Shornikova I.M. Indeks privlekatel'nosti lekarstvennyh sredstv kak instrument personalizirovannoy terapii pri saharnom diabete 2 tipa // Zdravoohranenie Chuvashii. - 2015. - № 2. - S. 27-29.
4. Ametov A.S. Proekt klinicheskih rekomendaciy Profilaktika razvitiya saharnogo diabeta 2 tipa: rol' i mesto metformina // Endokrinologiya. - 2017. - № 1. - S. 1-10.
5. Semakina S.M., Madyanov I.V., Markova T.N., Kichigin V.A., Borisova L.V. Vliyanie metformina na soderzhanie v krovi degidroepiandrosterona sul'fata u pacientov s metabolicheskim sindromom // Prakticheskaya medicina. - 2011. - № 6 (54). - S. 165-169.
6. Morgunov L.Yu. Pleyotropnye effekty metformina // Issledovaniya i praktika v medicine. - 2014. №1(1). - S. 62-68.
7. Madyanov I.V., Madyanova T.S. Sindrom polikistoznyh yaichnikov u devochek-podrostkov: kliniko-metabolicheskie osobennosti i perspektivy primeneniya metformina // Prakticheskaya medicina. - 2010. - № 4. - S 86-89.
8. Pryor R.,Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets // Biochem. J. - 2015; № 471(3). - R. 307-322.
9. Meshkani, S.E., Mahdian, D., Abbaszadeh-Goudarzi, K. et al. Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning // J. Endocrinol Invest. - 2019, May 16. - R. 1-19. DOI:https://doi.org/10.1007/s40618-019-01060-3
10. R-R Wu, F-Y Zhang, K-M Gao et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials // Mol Psychiatry. - 2016, Nov. - № 21(11). - R. 1537-1544. DOI:https://doi.org/10.1038/mp.2015.221. Epub 2016 Jan 26.
11. Hachaturyan N.E, Egshatyan L.V.Modulyaciya kishechnoy mikrobioty metforminom // Effektivnaya farmakoterapiya. - 2017. - № 43. - S. 20-29.
12. Wouter De Haes et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2 - Proceedings of the National Academy of Sciences, 2014. DOI:https://doi.org/10.1073/pnas.1321776111
13. Misnikova I.V. Metformin prolongirovannogo deystviya kak preparat pervogo vybora v lechenii saharnogo diabeta 2 tipa // Effektivnaya farmakoterapiya. - 2017. № 17: - S. 18-22.
14. Verbovoy A.F., Sharonova L.A., Dolgih Yu.A. Sovremennye vozmozhnosti lecheniya saharnogo diabeta 2 tipa // Poliklinika. - 2017. - № 1-2. - S. 16-19.
15. Adem Y. Dawed, Kaixin Zhou, Nienke van Leeuwen et al. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study // Diabetes Care. - Jun 2019. - № 42 (6). - R. 1027-1033. DOI:https://doi.org/10.2337/dc18-2182
16. Hermans M.P., Ahn S.A. Rousseau M.F. What is the phenotype of patients with gastrointestinal intolerance to metformin? // Diabetes Metab. - 2013. - № 39(4). - R. 322-329.
17. McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract // Diabetologia. - 2016. - № 59. - R. 426. DOI:https://doi.org/10.1007/s00125-015-3844-9
18. Siavash M, Tabbakhian M, Sabzghabaee AM, Razavi N. Severity of gastrointestinal side effects of metformin tablet compared to metformin capsule in type 2 diabetes mellitus patients // J Res Pharm Pract. - 2017. - № 6. R. 73-76. DOI:https://doi.org/10.4103/jrpp.JRPP_17_2
19. Nikitin I.G., Baykova I.E., Gogova L.M., Volynkina V.M., Sarkisyan K.N. Sindrom razdrazhennogo kishechnika: kliniko-diagnosticheskie osobennosti // RMZh. Medicinskoe obozrenie. - 2016. - №26. - S. 1805-1810.
